LFVN Lifevantage Corp
FY2025 10-K
Lifevantage Corp (LFVN) filed its fiscal year 2025 10-K annual report with the SEC on Sep 4, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Direct sales of nutrigenomic-based dietary supplements and wellness products promoting health activation through genetic pathways
- • New product emphasis: Launched patent-pending MindBody GLP-1 System™ targeting gut-brain axis for appetite control and weight management
Management Discussion & Analysis
- • Cash and equivalents $20.2M at June 30, 2025, up $3.3M from $16.9M at June 30, 2024
- • Net cash from operations $11.9M in FY2025 vs $12.2M in FY2024, slight decrease due to inventory and deposits
Risk Factors
- • Cybersecurity risk oversight by audit committee with direct board reporting on material incidents and financial effects
- • CIIO with 40+ years IT security experience leads cybersecurity program addressing risk detection and mitigation
Financial SummaryXBRL
Revenue
$229M
Net Income
$10M
Gross Margin
80.4%
Operating Margin
5.3%
Net Margin
4.3%
ROE
28.3%
Total Assets
$72M
EPS (Diluted)
$0.75
Operating Cash Flow
$12M
Source: XBRL data from Lifevantage Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Lifevantage Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.